Epigenetic inactivation of SPINT2 is associated with tumor suppressive function in esophageal squamous cell carcinoma

Experimental Cell Research

Volumn 322, Issue 1, 2014, Pages 149-158

  Yue, Dongli ^a   Fan, Qingxia ^a   Chen, Xinfeng ^a   Li, Feng ^a   Wang, Liping ^a   Huang, Lan ^a   Dong, Wenjie ^a   Chen, Xiaoqi ^a   Zhang, Zhen ^a   Liu, Jinyan ^a,b   Wang, Fei ^a,b   Wang, Meng ^a   Zhang, Bin ^a,c   Zhang, Yi ^a,b  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b ZHENGZHOU UNIVERSITY   (China)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Esophageal squamous cell carcinoma (ESCC); Methylation; SPINT2

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; MESSENGER RNA;

ADULT; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; EPIGENETICS; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROMOTER REGION; SEQUENCE ANALYSIS; SPINT2 GENE; SURVIVAL TIME; TUMOR SUPPRESSOR GENE;

ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC); METHYLATION; SPINT2;

ADULT; AGED; AGED, 80 AND OVER; AZACITIDINE; CARCINOMA, SQUAMOUS CELL; DNA METHYLATION; ESOPHAGEAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENES, TUMOR SUPPRESSOR; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PROMOTER REGIONS, GENETIC; TUMOR CELLS, CULTURED;

EID: 84893798030     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2013.11.009     Document Type: Article

References (34)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61:69-90.
2. Ma S., Bao J.Y., Kwan P.S., Chan Y.P., Tong C.M., Fu L., Zhang N., Tong A.H., Qin Y.R., Tsao S.W., Chan K.W., Lok S., Guan X.Y. Identification of PTK6, via RNA sequencing analysis, as a suppressor of esophageal squamous cell carcinoma. Gastroenterology 2012, 143(675-686):e671-612.
3. A. Jemal, R. Siegel, J. Xu, E. Ward, Cancer statistics, 2010, CA Cancer J. Clin.60 (2010) 277-300.
4. Wang L.D., Zhou F.Y., Li X.M., Sun L.D., Song X., Jin Y., Li J.M., Kong G.Q., Qi H., Cui J., Zhang L.Q., Yang J.Z., Li J.L., Li X.C., Ren J.L., Liu Z.C., Gao W.J., Yuan L., Wei W., Zhang Y.R., Wang W.P., Sheyhidin I., Li F., Chen B.P., Ren S.W., Liu B., Li D., Ku J.W., Fan Z.M., Zhou S.L., Guo Z.G., Zhao X.K., Liu N., Ai Y.H., Shen F.F., Cui W.Y., Song S., Guo T., Huang J., Yuan C., Wu Y., Yue W.B., Feng C.W., Li H.L., Wang Y., Tian J.Y., Lu Y., Yuan Y., Zhu W.L., Liu M., Fu W.J., Yang X., Wang H.J., Han S.L., Chen J., Han M., Wang H.Y., Zhang P., Dong J.C., Xing G.L., Wang R., Guo M., Chang Z.W., Liu H.L., Guo L., Yuan Z.Q., Liu H., Lu Q., Yang L.Q., Zhu F.G., Yang X.F., Feng X.S., Wang Z., Li Y., Gao S.G., Qige Q., Bai L.T., Yang W.J., Lei G.Y., Shen Z.Y., Chen L.Q., Li E.M., Xu L.Y., Wu Z.Y., Cao W.K., Wang J.P., Bao Z.Q., Chen J.L., Ding G.C., Zhuang X., Zhou Y.F., Zheng H.F., Zhang Z., Zuo X.B., Dong Z.M., Fan D.M., He X., Wang J., Zhou Q., Zhang Q.X., Jiao X.Y., Lian S.Y., Ji A.F., Lu X.M., Wang J.S., Chang F.B., Lu C.D., Chen Z.G., Miao J.J., Fan Z.L., Lin R.B., Liu T.J., Wei J.C., Kong Q.P., Lan Y., Fan Y.J., Gao F.S., Wang T.Y., Xie D., Chen S.Q., Yang W.C., Hong J.Y., Wang L., Qiu S.L., Cai Z.M., Zhang X.J. Genome-wide association study of esophageal squamous cell carcinoma in Chinese subjects identifies susceptibility loci at PLCE1 and C20orf54. Nat. Genet. 2010, 42:759-763.
5. Engel L.S., Chow W.H., Vaughan T.L., Gammon M.D., Risch H.A., Stanford J.L., Schoenberg J.B., Mayne S.T., Dubrow R., Rotterdam H., West A.B., Blaser M., Blot W.J., Gail M.H., Fraumeni J.F. Population attributable risks of esophageal and gastric cancers. J. Natl. Cancer Inst. 2003, 95:1404-1413.
6. Kawaguchi T., Qin L., Shimomura T., Kondo J., Matsumoto K., Denda K., Kitamura N. Purification and cloning of hepatocyte growth factor activator inhibitor type 2, a Kunitz-type serine protease inhibitor. J. Biol. Chem. 1997, 272:27558-27564.
7. Delaria K.A., Muller D.K., Marlor C.W., Brown J.E., Das R.C., Roczniak S.O., Tamburini P.P. Characterization of placental bikunin, a novel human serine protease inhibitor. J. Biol. Chem. 1997, 272:12209-12214.
8. Marlor C.W., Delaria K.A., Davis G., Muller D.K., Greve J.M., Tamburini P.P. Identification and cloning of human placental bikunin, a novel serine protease inhibitor containing two Kunitz domains. J. Biol. Chem. 1997, 272:12202-12208.
9. Huang H.P., Chang M.H., Chen Y.T., Hsu H.Y., Chiang C.L., Cheng T.S., Wu Y.M., Wu M.Z., Hsu Y.C., Shen C.C., Lee C.N., Chuang Y.H., Hong C.L., Jeng Y.M., Chen P.H., Chen H.L., Lee M.S. Persistent elevation of hepatocyte growth factor activator inhibitors in cholangiopathies affects liver fibrosis and differentiation. Hepatology 2012, 55:161-172.
10. Tung E.K., Wong C.M., Yau T.O., Lee J.M., Ching Y.P., Ng I.O. HAI-2 is epigenetically downregulated in human hepatocellular carcinoma, and its Kunitz domain type 1 is critical for anti-invasive functions. Int. J. Cancer 2009, 124:1811-1819.
11. Dong W., Chen X., Xie J., Sun P., Wu Y. Epigenetic inactivation and tumor suppressor activity of HAI-2/SPINT2 in gastric cancer. Int. J. Cancer 2010, 127:1526-1534.
12. Nakamura K., Abarzua F., Kodama J., Hongo A., Nasu Y., Kumon H., Hiramatsu Y. Expression of hepatocyte growth factor activator inhibitors (HAI-1 and HAI-2) in ovarian cancer. Int. J. Oncol. 2009, 34:345-353.
13. Nakamura K., Abarzua F., Hongo A., Kodama J., Nasu Y., Kumon H., Hiramatsu Y. Hepatocyte growth factor activator inhibitor-2 (HAI-2) is a favorable prognosis marker and inhibits cell growth through the apoptotic pathway in cervical cancer. Ann. Oncol. 2009, 20:63-70.
14. Morris M.R., Gentle D., Abdulrahman M., Maina E.N., Gupta K., Banks R.E., Wiesener M.S., Kishida T., Yao M., Teh B., Latif F., Maher E.R. Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma. Cancer Res. 2005, 65:4598-4606.
15. Tong M., Chan K.W., Bao J.Y., Wong K.Y., Chen J.N., Kwan P.S., Tang K.H., Fu L., Qin Y.R., Lok S., Guan X.Y., Ma S. Rab25 is a tumor suppressor gene with antiangiogenic and anti-invasive activities in esophageal squamous cell carcinoma. Cancer Res. 2012, 72:6024-6035.
16. Kong K.L., Kwong D.L., Fu L., Chan T.H., Chen L., Liu H., Li Y., Zhu Y.H., Bi J., Qin Y.R., Law S.Y., Guan X.Y. Characterization of a candidate tumor suppressor gene uroplakin 1A in esophageal squamous cell carcinoma. Cancer Res. 2010, 70:8832-8841.
17. Zhu Y.H., Fu L., Chen L., Qin Y.R., Liu H., Xie F., Zeng T., Dong S.S., Li J., Li Y., Dai Y., Xie D., Guan X.Y. Downregulation of the Novel Tumor Suppressor DIRAS1 predicts poor prognosis in esophageal squamous cell carcinoma. Cancer Res. 2013, 73:2298-2309.
18. Kong K.L., Kwong D.L., Chan T.H., Law S.Y., Chen L., Li Y., Qin Y.R., Guan X.Y. MicroRNA-375 inhibits tumour growth and metastasis in oesophageal squamous cell carcinoma through repressing insulin-like growth factor 1 receptor. Gut 2012, 61:33-42.
19. Nobeyama Y., Okochi-Takada E., Furuta J., Miyagi Y., Kikuchi K., Yamamoto A., Nakanishi Y., Nakagawa H., Ushijima T. Silencing of tissue factor pathway inhibitor-2 gene in malignant melanomas. Int. J. Cancer 2007, 121:301-307.
20. Boatright K.M., Salvesen G.S. Mechanisms of caspase activation. Curr. Opin. Cell Biol. 2003, 15:725-731.
21. Sarbia M., Porschen R., Borchard F., Horstmann O., Willers R., Gabbert H.E. p53 protein expression and prognosis in squamous cell carcinoma of the esophagus. Cancer 1994, 74:2218-2223.
22. Shimada H., Takeda A., Nabeya Y., Okazumi S.I., Matsubara H., Funami Y., Hayashi H., Gunji Y., Kobayashi S., Suzuki T., Ochiai T. Clinical significance of serum vascular endothelial growth factor in esophageal squamous cell carcinoma. Cancer 2001, 92:663-669.
23. Samejima R., Kitajima Y., Yunotani S., Miyazaki K. Cyclin D1 is a possible predictor of sensitivity to chemoradiotherapy for esophageal squamous cell carcinoma. Anticancer Res. 1999, 19:5515-5521.
24. Brockmann J.G., Nottberg H., Glodny B., Heinecke A., Senninger N.J. CYFRA 21-1 serum analysis in patients with esophageal cancer. Clin. Cancer Res. 2000, 6:4249-4252.
25. Shimada H., Takeda A., Arima M., Okazumi S., Matsubara H., Nabeya Y., Funami Y., Hayashi H., Gunji Y., Suzuki T., Kobayashi S., Ochiai T. Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma. Cancer 2000, 89:1677-1683.
26. Rosen E.M., Nigam S.K., Goldberg I.D. Scatter factor and the c-met receptor: a paradigm for mesenchymal/epithelial interaction. J. Cell Biol. 1994, 127:1783-1787.
27. Boros P., Miller C.M. Hepatocyte growth factor: a multifunctional cytokine. Lancet 1995, 345:293-295.
28. Abounader R., Laterra J. Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis. Neuro. Oncol. 2005, 7:436-451.
29. Li Y., Lal B., Kwon S., Fan X., Saldanha U., Reznik T.E., Kuchner E.B., Eberhart C., Laterra J., Abounader R. The scatter factor/hepatocyte growth factor: c-met pathway in human embryonal central nervous system tumor malignancy. Cancer Res. 2005, 65:9355-9362.
30. Grugan K.D., Miller C.G., Yao Y., Michaylira C.Z., Ohashi S., Klein-Szanto A.J., Diehl J.A., Herlyn M., Han M., Nakagawa H., Rustgi A.K. Fibroblast-secreted hepatocyte growth factor plays a functional role in esophageal squamous cell carcinoma invasion. Proc. Natl. Acad. Sci. USA 2010, 107:11026-11031.
31. Ren Y., Cao B., Law S., Xie Y., Lee P.Y., Cheung L., Chen Y., Huang X., Chan H.M., Zhao P., Luk J., Vande Woude G., Wong J. Hepatocyte growth factor promotes cancer cell migration and angiogenic factors expression: a prognostic marker of human esophageal squamous cell carcinomas. Clin. Cancer Res. 2005, 11:6190-6197.
32. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat. Rev. Genet. 2007, 8:286-298.
33. Parr C., Watkins G., Mansel R.E., Jiang W.G. The hepatocyte growth factor regulatory factors in human breast cancer. Clin. Cancer Res. 2004, 10:202-211.
34. Kongkham P.N., Northcott P.A., Ra Y.S., Nakahara Y., Mainprize T.G., Croul S.E., Smith C.A., Taylor M.D., Rutka J.T. An epigenetic genome-wide screen identifies SPINT2 as a novel tumor suppressor gene in pediatric medulloblastoma. Cancer Res. 2008, 68:9945-9953.